Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.
Saved in:
| Title: | Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. |
|---|---|
| Authors: | Jamroze A; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Anmbreen.Jamroze@Roswellpark.org., Liu X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Hou S; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Jess Li W; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY, USA.; Department of Medicine and Department of Biomedical Sciences, Cedars-Sinai Medical Center, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Yu H; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Tracz A; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Jacobi J; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Li Q; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory for Oral Biomedicine of Ministry of Education (KLOBM), School and Hospital of Stomatology, Wuhan University, Wuhan, China., Nastiuk K; Departments of Cancer Genetics and Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Chen X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Huang J; Department of Pathology, Duke University School of Medicine, Durham, NC, USA., Lin K; Department of Epigenetics and Molecular Carcinogenesis, the University of Texas M.D Anderson Cancer Center, Houston, TX, USA., Liu M; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA., Cai C; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA., Lu Y; Department of Epigenetics and Molecular Carcinogenesis, the University of Texas M.D Anderson Cancer Center, Houston, TX, USA., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Kirk JS; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Chatta G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Tang DG; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org.; Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY, USA. Dean.Tang@Roswellpark.org. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 May 01; Vol. 11 (1). Date of Electronic Publication: 2026 May 01. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2059-3635 |
|---|---|
| DOI: | 10.1038/s41392-026-02700-w |
